Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

COVID-19 prevalence in 161 countries and over time

View ORCID ProfileStilianos Louca
doi: https://doi.org/10.1101/2020.12.01.20241539
Stilianos Louca
1Department of Biology, University of Oregon, Eugene, USA
2Institute of Ecology and Evolution, University of Oregon, Eugene, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stilianos Louca
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Effectively evaluating, controlling and predicting the course of the COVID-19 pandemic requires knowledge of the true number of infections in the population. This number, however, generally differs substantially from the number of confirmed cases due to a large fraction of asymptomatic infections as well as geographically and temporally variable testing effort and strategies. Here I use age-stratified death count statistics, published age-dependent infection fatality risks and stochastic modeling to estimate the true prevalence and growth of COVID-19 infections among adults (age ≥ 20 years) in 161 countries, from early 2020 until November 1, 2020. My predictions are largely consistent with data from multiple previous nationwide seroprevalence surveys. As of November 1, 2020, the nationwide cumulative COVID-19 prevalence (past and current infections relative to the population size) is estimated at 31% (95%-CI 22-50) for Peru, 27% (17–41) for Mexico, 22% (14–34) for Brazil, 12% (7.2-20) for the US, 11% (6.4–18) for the United Kingdom, 8.2% (5.2–15) for France, 7.4% (4.9–13) for Sweden, 4.2% (2.5–6.8) for Canada, 1.8% (1.2–3) for Germany and 0.12% (0.074–0.26) for Japan. These time-resolved estimates expand the possibilities to evaluate the factors influencing the pandemic’s progression and to assess vaccination needs around the world. Periodically updated estimates are available at: www.loucalab.com/archive/COVID19prevalence

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by a US National Science Foundation RAPID grant #2028986.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

N/A.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data used in this manuscript were obtained from publicly accessible sources.

https://covid19.who.int/table

https://population.un.org/wpp/Download/Standard/CSV

https://osf.io/7tnfh

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 02, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
COVID-19 prevalence in 161 countries and over time
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
COVID-19 prevalence in 161 countries and over time
Stilianos Louca
medRxiv 2020.12.01.20241539; doi: https://doi.org/10.1101/2020.12.01.20241539
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
COVID-19 prevalence in 161 countries and over time
Stilianos Louca
medRxiv 2020.12.01.20241539; doi: https://doi.org/10.1101/2020.12.01.20241539

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (451)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5258)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (757)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (698)
  • Health Policy (358)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (163)
  • Infectious Diseases (except HIV/AIDS) (5867)
  • Intensive Care and Critical Care Medicine (361)
  • Medical Education (104)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (764)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (142)
  • Occupational and Environmental Health (231)
  • Oncology (479)
  • Ophthalmology (152)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (862)
  • Public and Global Health (2011)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (285)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)